UMB Bank n.a. Cuts Stock Position in Novo Nordisk A/S (NYSE:NVO)

UMB Bank n.a. decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 40,820 shares of the company’s stock after selling 610 shares during the quarter. UMB Bank n.a.’s holdings in Novo Nordisk A/S were worth $2,835,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Victory Capital Management Inc. boosted its position in Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock valued at $5,410,000 after buying an additional 23,223 shares during the period. Bryn Mawr Capital Management LLC boosted its holdings in Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after purchasing an additional 30,420 shares during the period. DSM Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 16.7% in the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock valued at $172,678,000 after purchasing an additional 286,912 shares during the period. Channing Global Advisors LLC acquired a new position in Novo Nordisk A/S during the 4th quarter worth $354,000. Finally, Compagnie Lombard Odier SCmA increased its holdings in Novo Nordisk A/S by 5.0% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 67,745 shares of the company’s stock worth $5,827,000 after purchasing an additional 3,200 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 2.8%

NVO stock opened at $74.70 on Monday. The stock has a market cap of $335.22 billion, a P/E ratio of 22.71, a PEG ratio of 0.90 and a beta of 0.66. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company’s 50 day moving average is $65.87 and its two-hundred day moving average is $80.38.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The firm had revenue of $11.87 billion during the quarter. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the subject of several recent research reports. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Friday. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an “underperform” rating for the company. BMO Capital Markets reissued a “market perform” rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Finally, Dbs Bank lowered Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $128.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.